Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pfizer

Related PFE
Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary
Stocks Mixed Despite Better-Than-Expected GDP
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), and raised its price target from $27.00 to $31.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Pfizer closed on Tuesday at $26.74.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters